2018 - Page 2 of 2 - Pershing Square Foundation

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways

February 27th, 2018 / BUSINESS WIRE

–Versant-seeded company focused on applying novel biology to boost anti-tumor immunity– —Foundational science stems from landmark ER stress biology research at Weill Cornell Medicine— —Michael Aberman, M.D., former SVP of Strategy for Regeneron, appointed as President and Chief Executive Officer— NEW YORK–(BUSINESS WIRE)–Quentis Therapeutics Inc., a biotechnology company pursuing next-generation immuno-oncology research and drug development, … Continued

Machine Learning for Building Personalized Cancer Nanomedicines: Interview with Dr. Daniel Heller

February 16th, 2018 / Conn Hastings / Medgadget

Researchers at the Sloan Kettering Institute and the Weill Cornell Graduate School of Medical Sciences in New York have developed a machine learning approach to design personalized nanoparticle therapies for cancer. Personalized cancer therapies aim to provide a treatment that is tailored to the genetic makeup of a patient’s tumor. They can still cause side effects, however, when they … Continued

Intravital Imaging Offers View of Cancer Cell Interaction With Immune Response

January 19th, 2018 / Valerie Neff Newitt / Oncology Times

Far from her native Copenhagen, Denmark, Mikala Egeblad, PhD, works tirelessly to find a means to reduce cancer metastases and recurrences. The significance of her work, now centered in her lab at Cold Spring Harbor Laboratory, Long Island, N.Y., where she is an Associate Professor, has resulted in the Department of Defense Breast Cancer Research … Continued

New immunotherapy approach boosts body’s ability to destroy cancer cells

January 12th, 2018 / The Rockefeller University

Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes after infectious microorganisms. Yet these treatments only benefit some patients, and remain ineffective in the vast majority of cases. … Continued

Throwing molecular wrench into gene control machine leads to ‘melting away’ of leukemia

January 9th, 2018 / Cold Spring Harbor Laboratory

PUBLIC RELEASE: 8-JAN-2018 Cold Spring Harbor, NY – Cancer researchers today announced they have developed a way of sidelining one of the most dangerous “bad actors” in leukemia. Their approach depends on throwing a molecular wrench into the gears of an important machine that sets genes into motion, enabling cancer cells to proliferate. In tests in … Continued

News